Navigation Links
Acute Pain Global Clinical Trials Review, H2, 2013
Date:11/27/2013

London (PRWEB) November 27, 2013

Acute Pain Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, “Acute Pain Global Clinical Trials Review, H2, 2013" provides data on the Acute Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

-Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
-Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
-Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

-Understand the dynamics of a particular indication in a condensed manner
-Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
-Obtain discontinued trial listing for trials across the globe
-Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Con
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
2. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
3. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
4. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... , SHANGHAI, Nov. ... Drug Administration (SFDA) has approved the,investigational new drug application (IND) ... treat diabetes. This IND,approval allows Biolaxy to initiate its first ... is a disorder characteristic of high blood glucose and poor,metabolism. ...
... ... by laboratories participating in or generating DNA records for the National DNA Index System. ... Madison, WI USA (PRWEB) -- ... laboratories participating in, or generating DNA records for, the National DNA Index System (NDIS). NDIS ...
... HTL , TORONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorne Ltd. (TSX-V: ... systems and instruments for the stem cell research and fertility clinic ... ended September 30, 2009. , , Q3 2009 ... compared with $1.43 million in Q3 2008, - ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... the Electronic Nose, which has the potential to diagnose ... grant from Grand Challenges Canada and the Bill & ... testing of this ground-breaking technology. The ... able to detect TB immediately and non-invasively from the ...
... family of compounds that includes one of the most ... treatments. But the difficulty producing these complex molecules in ... family for further drug leads. Now, a group of ... step toward the goal of synthetically producing Taxol and ...
... name "Sleeping Beauty" has helped to unlock vital clues ... A study published today used the Sleeping Beauty transposon ... drive colorectal cancer, identifying many more than previously thought. ... human cancer, which provides strong evidence that they are ...
Cached Biology News:Creating an 'electronic nose' to sniff out tuberculosis from a patient's breath 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 3Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 4Researchers discover genes involved in colorectal cancer 2